Board Member
Ani Pharmaceuticals Inc (ANIP)Equibles does not estimate personal net worth.
Get an email with a short summary when Ani Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get ANIP alertsNikhil Lalwani is recorded as Board Member at Ani Pharmaceuticals Inc (ANIP) since May 21, 2026 and CEO at Ani Pharmaceuticals Inc (ANIP). The newest filing on record that lists Nikhil Lalwani as CEO at Ani Pharmaceuticals Inc (ANIP) is dated April 9, 2026. Ani Pharmaceuticals Inc reported in an 8-K filed May 21, 2026 that Nikhil Lalwani was appointed Director, effective May 21, 2026. Ani Pharmaceuticals Inc reported in an 8-K filed May 23, 2025 that Nikhil Lalwani was appointed director, effective May 22, 2025. Ani Pharmaceuticals Inc reported in an 8-K filed May 25, 2023 that Nikhil Lalwani was appointed director, effective May 23, 2023. The proxy statement of Ani Pharmaceuticals Inc reports total compensation of $10,278,620 for Nikhil Lalwani in fiscal 2025, including a base salary of $837,409. Disclosed compensation is on record for 6 fiscal years. Nikhil Lalwani has spoken on 24 earnings calls and 4 other investor events across 1 company, most recently for Ani Pharmaceuticals Inc on September 15, 2026. Ani Pharmaceuticals Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Ani Pharmaceuticals Inc includes Patrick D. Walsh (CEO and Board Member), Thomas J. Haughey (Chairman), Stephen Carey (CFO) and 7 others.
“The election of seven (7) director nominees, each to serve until the Company’s 2027 Annual Meeting of Stockholders and thereafter until their successors are duly elected and qualified, or until their earlier death, resignation or removal”
“The election of eight (8) directors to serve until the Company's 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their successors shall have been duly elected and qualified”
“We have two acids with durability and growth. Our lead acid, purified coprofen gel, is approved across multiple indications, 20 plus, of which we focus on six or seven.”
“I'm really pleased with the progress made by the team across the last six years. We have made several important steps for the company and the company's trajectory, starting with when I joined as CEO in 2020, we were largely a BD shop.”
“So, A&I is a rapidly growing, profitable biopharmaceutical company focused on rare disease. Our primary focus and strategy is to accelerate our transformation into a leading rare disease company.”
“Good morning, everyone, and thank you for joining us for ANI's second quarter 2026 earnings call. Starting on slide 5, our entire organization demonstrated outstanding focus during the second quarter as we continued to transform E&I into a leading rare disease company.”
“ANI is building a leading rare disease company, and in 2026, we're focused on accelerating our transformation into a leading rare disease company. Our guidance for the year is $1,080,000 to $1,140,000 for revenues and $285,000,000 to $300,000,000 in adjusted non-GAAP EBITDA.”
2026-05-21–present
Start not stated–present
Last confirmed April 9, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
2026-05-21–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Ani Pharmaceuticals Inc (ANIP) | President and Chief Executive Officer | $837,409 | $10,278,620 |
| 2024 | Ani Pharmaceuticals Inc (ANIP) | President and Chief Executive Officer | $794,914 | $8,859,402 |
| 2023 | Ani Pharmaceuticals Inc (ANIP) | President and Chief Executive Officer | $764,341 | $8,078,353 |
| 2022 | Ani Pharmaceuticals Inc (ANIP) | President and Chief Executive Officer | $736,812 | $5,112,087 |
| 2021 | Ani Pharmaceuticals Inc (ANIP) | President and Chief Executive Officer | $715,347 | $6,541,060 |
| 2020 | Ani Pharmaceuticals Inc (ANIP) | President and Chief Executive Officer | $199,231 | $3,715,036 |
